Created in 2015, TargEDys has benefited from investments from major players in the microbiome sphere: NCI, Pontifax, Seventure and Biocodex. These investments have allowed TargEDys to develop the science into finished products, and to make these products available to a large number of consumers through distribution agreements in several countries.
End of May 2023, the French family company Biocodex has acquired 100% of TargEDys shares, to consolidate the groups strong ambition in the Microbiome and accelerate TargEDys development globally.
Clic here for more information.
Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,600 employees, Biocodex generated net revenues of above €500 million in 2022, including 35% in France and 65% internationally. The group is present in 115 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.
Since 2019, Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal and Poland.